TOP TEN perturbations for 1552568_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1552568_at
Selected probe(set): 1552569_a_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1552568_at (1552569_a_at) across 6672 perturbations tested by GENEVESTIGATOR:

HCC study 18 (very advanced) / normal liver tissue

Relative Expression (log2-ratio):-3.916339
Number of Samples:3 / 10
Experimental HCC study 18 (very advanced)
Tumor tissue samples obtained from liver of patients with very advanced hepatocellular carcinoma (HCC) undergoing resection or liver transplantation. Very advanced HCC cases included moderately to poorly differentiated tumors with macrovascular invasion or diffuse liver involvement. Patients positive for HBV markers, with history of alcohol consumption, nonalcoholic steatohepatitis, hemochromatosis, other chronic liver diseases or prior locoregional treatment were excluded.
Control normal liver tissue
Normal liver tissue samples obtained from the healthy livers of patients undergoing resection for hepatic hemangioma, focal nodular hyperplasia, adenoma/cystadenoma, neuroendocrine tumor, and living donor liver transplantation.

HCC study 18 (very advanced) / HCC study 18 (early)

Relative Expression (log2-ratio):-3.579422
Number of Samples:3 / 5
Experimental HCC study 18 (very advanced)
Tumor tissue samples obtained from liver of patients with very advanced hepatocellular carcinoma (HCC) undergoing resection or liver transplantation. Very advanced HCC cases included moderately to poorly differentiated tumors with macrovascular invasion or diffuse liver involvement. Patients positive for HBV markers, with history of alcohol consumption, nonalcoholic steatohepatitis, hemochromatosis, other chronic liver diseases or prior locoregional treatment were excluded.
Control HCC study 18 (early)
Tumor tissue samples obtained from liver of patients with early hepatocellular carcinoma (HCC) undergoing resection or liver transplantation. Early HCC cases included well- to moderately differentiated tumors measuring 2-5 cm without vascular invasion/satellites, or 2-3 well-differentiated nodules measuring <3 cm (size range: 3-45 mm). Patients positive for HBV markers, with history of alcohol consumption, nonalcoholic steatohepatitis, hemochromatosis, other chronic liver diseases or prior locoregional treatment were excluded.

HCC study 18 (very advanced) / dysplastic liver nodule study 1

Relative Expression (log2-ratio):-3.4995794
Number of Samples:3 / 17
Experimental HCC study 18 (very advanced)
Tumor tissue samples obtained from liver of patients with very advanced hepatocellular carcinoma (HCC) undergoing resection or liver transplantation. Very advanced HCC cases included moderately to poorly differentiated tumors with macrovascular invasion or diffuse liver involvement. Patients positive for HBV markers, with history of alcohol consumption, nonalcoholic steatohepatitis, hemochromatosis, other chronic liver diseases or prior locoregional treatment were excluded.
Control dysplastic liver nodule study 1
Dysplastic nodule tissue samples obtained from liver of HCV infected patients undergoing resection or liver transplantation. Patients positive for HBV markers, with history of alcohol consumption, nonalcoholic steatohepatitis, hemochromatosis, other chronic liver diseases or prior locoregional treatment were excluded.

HCC study 18 (very advanced) / hepatitis C study 10

Relative Expression (log2-ratio):-3.3478937
Number of Samples:3 / 13
Experimental HCC study 18 (very advanced)
Tumor tissue samples obtained from liver of patients with very advanced hepatocellular carcinoma (HCC) undergoing resection or liver transplantation. Very advanced HCC cases included moderately to poorly differentiated tumors with macrovascular invasion or diffuse liver involvement. Patients positive for HBV markers, with history of alcohol consumption, nonalcoholic steatohepatitis, hemochromatosis, other chronic liver diseases or prior locoregional treatment were excluded.
Control hepatitis C study 10
Cirrhotic tissue samples obtained from liver of HCV infected patients undergoing resection or liver transplantation. Ten out of 13 samples were obtained from patients with hepatocellular carcinoma. Patients positive for HBV markers, with history of alcohol consumption, nonalcoholic steatohepatitis, hemochromatosis, other chronic liver diseases or prior locoregional treatment were excluded.

HCC study 18 (very advanced) / HCC study 18 (very early)

Relative Expression (log2-ratio):-3.1587534
Number of Samples:3 / 5
Experimental HCC study 18 (very advanced)
Tumor tissue samples obtained from liver of patients with very advanced hepatocellular carcinoma (HCC) undergoing resection or liver transplantation. Very advanced HCC cases included moderately to poorly differentiated tumors with macrovascular invasion or diffuse liver involvement. Patients positive for HBV markers, with history of alcohol consumption, nonalcoholic steatohepatitis, hemochromatosis, other chronic liver diseases or prior locoregional treatment were excluded.
Control HCC study 18 (very early)
Tumor tissue samples obtained from liver of patients with very early hepatocellular carcinoma (HCC) undergoing resection or liver transplantation. Very early HCC cases included well-differentiated tumors measuring ≤2 cm in diameter with no vascular invasion/satellites (size range: 8-20 mm). Patients positive for HBV markers, with history of alcohol consumption, nonalcoholic steatohepatitis, hemochromatosis, other chronic liver diseases or prior locoregional treatment were excluded.

HCC study 27 (young; training) / normal liver tissue (young; training)

Relative Expression (log2-ratio):-3.0243168
Number of Samples:16 / 15
Experimental HCC study 27 (young; training)
Primary tumor tissue samples obtained from the liver of young patients (≤ 40 years old) with hepatocellular carcinoma assigned to a training cohort.
Control normal liver tissue (young; training)
Normal liver tissue samples obtained from young patients (≤ 40 years old) with hepatocellular carcinoma (HCC) assigned to a training cohort.

HCC study 23 (portal vein infiltration) / adjacent liver tissue

Relative Expression (log2-ratio):-2.7218752
Number of Samples:3 / 10
Experimental HCC study 23 (portal vein infiltration)
Tumor liver tissue samples derived from patients with hepatocellular carcinoma (HCC) with portal vein infiltration. Samples were derived by laser capture microdissection (LCM) from patients with HCC from the Chinese National Human Genome Center at Shanghai.
Control adjacent liver tissue
Normal adjacent liver tissue samples derived from patients with hepatocellular carcinoma (HCC). Samples were derived by laser capture microdissection (LCM) from patients with HCC from the Chinese National Human Genome Center at Shanghai.

theophylline study 4 (10000uM) / vehicle (medium) treated hepatocyte sample

Relative Expression (log2-ratio):-2.378253
Number of Samples:2 / 2
Experimental theophylline study 4 (10000uM)
Hepatocytes treated with compound: theophylline (10000uM; CHEMBL190) for 8 hours. ATC code:
Control vehicle (medium) treated hepatocyte sample
Hepatocytes treated with vehicle (medium) for 8 hours.

caffeine study 1 (7500uM) / vehicle (medium) treated hepatocyte sample

Relative Expression (log2-ratio):-2.3756056
Number of Samples:2 / 2
Experimental caffeine study 1 (7500uM)
Hepatocytes treated with compound: caffeine (7500uM; CHEMBL113) for 8 hours. ATC code:
Control vehicle (medium) treated hepatocyte sample
Hepatocytes treated with vehicle (medium) for 8 hours.

caffeine study 2 (7500uM) / vehicle (medium) treated hepatocyte sample

Relative Expression (log2-ratio):-2.3696976
Number of Samples:2 / 2
Experimental caffeine study 2 (7500uM)
Hepatocytes treated with compound: caffeine (7500uM; CHEMBL113) for 24 hours. ATC code:
Control vehicle (medium) treated hepatocyte sample
Hepatocytes treated with vehicle (medium) for 24 hours.